Takara Bio Of Japan To Jointly Develop Liver Cancer Therapy With Chinese University
This article was originally published in PharmAsia News
Executive Summary
Takara Bio announced Sept. 1 the company will jointly develop a liver cancer therapy with Zhongshan University Cancer Center in Guangzhou, China. Takara will combine its own immunotherapy with Zhongshan University's radio frequency therapy to kill cancer cells. The two parties plan to conduct the research on 30 patients in two years. According to Takara, immunotherapy combined with radio frequency therapy could lead to prevention of cancer recurrence. (Click here for more - Japanese language
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.